Improved Medication and Care to Achieve Lipid Targets After Carotid Surgery

ConditionsDyslipidaemias Carotid Artery Stenoses

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorBarmherzige Brüder Linz

About this trial

The goal of this clinical trial is to find out if patients who receive extra support stay on their cholesterol-lowering therapy and therefore have lower cholesterol levels after 4 months. Extra support means regular phone calls and close monitoring before and after carotid artery surgery. The study compares this approach to usual care.

Participants will:

Be randomly assigned to either standard care or extra support for 4 months. Receive cholesterol-lowering treatment and attend follow-up visits.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age >17 years

Diagnosed carotid artery stenosis

Planned carotid endarterectomy

LDL cholesterol >55 mg/dL

Disqualifiers

Ongoing treatment with PCSK9 inhibitors

Carotid surgery for reasons other than stenosis (e.g., traumatic injury)

Trial design

Design model

Parallel

Treatments tested in this trial

Prompt Medication Adjustment and Intensive Follow-up
Behavioral
Participants receive prompt adjustment of lipid-lowering therapy perioperatively and 6-8 weeks after carotid endarterectomy to achieve guideline-recommended LDL-C targets, combined with intensive follow-up visits and laboratory monitoring. Intensive follow-up visits and laboratory monitoring of lipid parameters are performed at 6-8 weeks and again at 12-16 weeks postoperatively to optimize lipid management.
Standard Care
Other intervention
Participants receive standard postoperative care according to guidelines, including lipid management and routine follow-up without additional early intervention or intensive monitoring. Lipid parameters are assessed only once at 12-16 weeks postoperatively.

Treatment groups

50 Participants

are divided into 2 treatment groups

Group A: Intensive Follow-upExperimental treatment 1 intervention

Group B: Standard CareActive comparator 1 intervention

Trial outcomes

Primary outcomes

Proportion of patients achieving the LDL-C target of <55 mg/dL

Time frame

12-16 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Barmherzige Brüder Linz

Lead sponsor

Johannes Kepler University of Linz

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: